Body composition predicts poor outcomes and reveals immunometabolic dysfunction via single‐cell profiling in anti‐BCMA CAR T‐treated myeloma

Abstract Chimeric antigen receptor (CAR) T‐cell therapy has transformed the treatment of relapsed or refractory multiple myeloma (RRMM), yet outcomes remain heterogenous. The prognostic role of body composition in this context is unknown. We retrospectively analyzed 108 RRMM patients treated with an...

Full description

Bibliographic Details

Main Authors:	Thomas C. Wiemers, Michael Rade, Nora Grieb, Maximilian Ferle, Tihomir Dermendzhiev, David Fandrei, Patrick Born, Luise Fischer, Sabine Seiffert, Anja Grahnert, Maik Friedrich, Ronny Baber, Markus Kreuz, Klaus H. Metzeler, Marco Herling, Carmen D. Herling, Madlen Jentzsch, Georg‐Nikolaus Franke, Andreas Boldt, Thomas Neumuth, Urvi A. Shah, Ulrike Köhl, Kristin Reiche, Timm Denecke, Uwe Platzbecker, Vladan Vučinić, Hans‐Jonas Meyer, Maximilian Merz
Format:	Artigo
Language:	Inglês
Published:	Wiley 2026-03-01
Series:	HemaSphere
Online Access:	https://doi.org/10.1002/hem3.70314
Tags:	Add Tag No Tags, Be the first to tag this record!